# Consensus checked against original sources: Injectable Peptide Stacks and Human Recovery

Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## CJC-1295 trial design, endpoints and access depth
Consensus correctly identified two blinded placebo-controlled ascending-dose trials and GH/IGF-I outcomes. Its own grounding snippets are labeled Abstract, despite a broader claim of Methods/Results validation. The original abstract confirms hormone activity and short tolerability, not clinical recovery; no original full-body access is asserted for this paper. [Original PMID16352683](https://pubmed.ncbi.nlm.nih.gov/16352683/). Access: abstract_metadata.

## Ipamorelin clinical endpoint and translational boundary
Consensus correctly reports a primary-null postoperative-ileus trial. The original randomized report gives meal-tolerance medians of25.3 and32.6 hours with p=0.15 and no significant key or secondary efficacy differences. This tests intravenous single-agent postoperative care, not the healthy-adult CJC-ipamorelin stack. Nonsignificance is not equivalence. [Original PMID25331030](https://pubmed.ncbi.nlm.nih.gov/25331030/). Access: abstract_metadata.

## CJC report overlap and biomarkers
Original Methods explicitly identify eleven men as a subset of a previously described cohort and repeat prior GH/IGF-I measurement procedures. The later serum-proteomic Results add candidate markers and correlations, not an independent clinical recovery experiment. Counts therefore group this report with the CJC pulsatility cohort rather than treating it as a new causal line. [Original PMID19386527](https://pubmed.ncbi.nlm.nih.gov/19386527/). Access: full_text_partial.

## GH-axis body composition versus function and power
The original MK-677 Methods define blinded randomized treatment and function tests including walking, stairs and chair rise, with primary power for fat-free mass and visceral fat. Original Results show GH/IGF-I and mass changes, no significant function change, and worsened glycemic measures. This independently strengthens the provider-described biomarker/function boundary while retaining the limitation that functional nulls were not adequately powered equivalence tests. [Original PMID18981485](https://pubmed.ncbi.nlm.nih.gov/18981485/). Access: full_text_partial.

## Tesamorelin indication and original endpoint hierarchy
Consensus used this trial as a rigorous indication-specific comparator. Original Methods verify HIV-related abdominal adiposity enrollment, blinded treatment, CT/MRS and metabolic monitoring; Results confirm visceral/liver-fat reduction and transient glucose or insulin-sensitivity signals. These endpoints do not demonstrate healthy-adult recovery or establish the net benefit of another secretagogue combination. [Original PMID25038357](https://pubmed.ncbi.nlm.nih.gov/25038357/). Access: full_text_partial.

## Latest component-dismantling animal result
The provider summary relies heavily on reviews for healing-peptide boundaries. The examined2026 original adds a four-arm thirty-two-rat Achilles-repair experiment: TB-500 alone showed significant mechanical benefit, and BPC-157 plus TB-500 did not add benefit over components. It strengthens the need for direct combination testing while preserving species, surgical-model and molecular-identity limits; it does not test CJC-ipamorelin. [Original PMID42542926](https://pubmed.ncbi.nlm.nih.gov/42542926/). Access: abstract_metadata.

## Commercial label versus clinical formulation identity
Consensus highlights the DAC versus similarly named marketed formulation boundary. The original analytical report identifies a twenty-nine-amino-acid peptide in an unknown product marketed as CJC-1295. Identity in that sample does not establish equivalence to the albumin-binding clinical formulation or market-wide safety and purity. [Original PMID21204297](https://pubmed.ncbi.nlm.nih.gov/21204297/). Access: abstract_metadata.

## Human ipamorelin target engagement
Original human dose-escalation PK/PD confirms a GH episode after intravenous ipamorelin. This supports the biological rationale retained in the review, but it is neither an injected-combination clinical efficacy trial nor a chronic recovery-safety test. Provider included counts and research-gap matrix cells are not used as numbers of direct human efficacy trials. [Original PMID10496658](https://pubmed.ncbi.nlm.nih.gov/10496658/). Access: abstract_metadata.

## Positive sprint result and fluid interpretation
Consensus correctly notes a short-lived sprint effect and extracellular-water-driven lean-mass gain. The original blinded96-athlete trial reports a3.9percent GH-associated sprint increase, no significant other performance changes and loss of the sprint effect after washout. This positive is retained rather than cherry-picking only null GH comparators; it is a different hormone exposure and endpoint from exact-stack recovery. [Original PMID20439575](https://pubmed.ncbi.nlm.nih.gov/20439575/). Access: abstract_metadata.

## Critical-illness safety boundary
The original two randomized high-dose GH trials show increased mortality in prolonged critical illness. This serious harm must remain bounded to its measured population and exposure; it cannot become an asserted CJC-ipamorelin mortality rate in healthy adults. [Original PMID10477776](https://pubmed.ncbi.nlm.nih.gov/10477776/). Access: abstract_metadata.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.